
BLTE Stock Forecast & Price Target
BLTE Analyst Ratings
Bulls say
Belite Bio Inc. is positioned for potential share appreciation over the next 12-18 months, primarily driven by anticipated updates regarding the Phase 3 clinical trials for its lead product, tinlarebant, targeting untreatable eye diseases. The company has demonstrated a solid cash position and an increased sample size for its Phase 3 PHOENIX trial, with strong enrollment figures, indicating robust investor interest following recent interim analysis updates. Additionally, the positive preliminary data from the Phase 2 studies and the heightened estimated pricing for tinlarebant suggest significant growth potential as the company aims to secure FDA approval for its treatments targeting eye diseases such as STGD1.
Bears say
Belite Bio Inc reported a significant net loss of $36.1 million in 2024, raising concerns regarding its financial sustainability amid ongoing clinical trials. The company faces substantial risks related to its drug candidate, tinlarebant, which include potential failures in clinical trials and regulatory approval that could hinder its path to commercialization in a competitive market. Furthermore, ongoing regulatory processes and the possibility of equity dilution add to the uncertainties surrounding the company’s financial outlook and viability.
This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BLTE Analyst Forecast & Price Prediction
Start investing in BLTE
Order type
Buy in
Order amount
Est. shares
0 shares